Press

MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)

Jul 17 • 4 min read

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat mental health disorders, today announced the issuance of a new patent by the United States Patent and Trademark Office (USPTO) covering MM120 (lysergide). MM120 is currently in clinical development for adults with generalized anxiety…

Psyched Wellness Adds Harmons to List of Retail Partners, Engages UNFI For Distribution, and Announces Appointment of Kyle Nazareth as Chief Financial Officer

Jul 17 • 3 min read

Toronto, Ontario–(Newsfile Corp. – July 17, 2024) – Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched“), a life sciences company focused on the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom, is pleased to update the markets with the latest list of specialty retailers…

Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial

Jul 16 • 4 min read

Vancouver, Canada, July 16, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug…

Braxia Scientific Announces Application for a Management Cease Trade Order For Late Filing of Audited Annual Financial Statements

Jul 16 • 3 min read

Toronto, Ontario–(Newsfile Corp. – July 15, 2024) – Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960), (“Braxia Scientific”, or the “Company”), today announced that it has made an application to the Ontario Securities Commission to approve a management cease trade order (“MCTO”) under National Policy 12-203 – Cease Trade Orders for Continuous Disclosure…

Algernon Pharmaceuticals Reports Results of Study Showing 93% Cough Suppression with Ifenprodil

Jul 16 • 4 min read

VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to report that ifenprodil achieved a 93% (p = 0.036) reduction in median cough count in an acute guinea pig citric acid challenge study. The multi-dose…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441